Close on the heels of a US district court ruling against its patent challenge of Pfizer's Lipitor, Ranbaxy Laboratories Ltd on Friday said it had entered into an out of court settlement with Cephalon Inc
In a release issued on February 13, FTC alleged that Cephalon's 'anti-competitive' scheme denies patients access to lower cost, generic versions of Provigil (modafinil) and forces consumers and other purchasers to pay hundreds of millions of dollars a year more for Provigil.
Cephalon, a US-based drug maker, has filed a lawsuit against Lupin Ltd and its US subsidiary Lupin Pharmaceuticals for challenging the patents on its sleep disorder drug Nuvigil.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances